$CDNA
CareDx, Inc.

2017 Q2 Form 10-Q Financial Statement

#000156459017017296 Filed on August 11, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q4 2016 Q2
Revenue $12.05M $10.86M $10.74M
YoY Change 12.21% 63.34% 50.58%
Cost Of Revenue $5.190M $6.480M $2.852M
YoY Change 81.98% 160.24% 13.72%
Gross Profit $6.860M $4.380M $7.883M
YoY Change -12.98% 5.29% 70.59%
Gross Profit Margin 56.95% 40.34% 73.43%
Selling, General & Admin $7.400M $7.100M $8.749M
YoY Change -15.42% 27.01% 80.21%
% of Gross Profit 107.87% 162.1% 110.99%
Research & Development $3.120M $3.150M $3.143M
YoY Change -0.73% 16.67% 25.22%
% of Gross Profit 45.48% 71.92% 39.87%
Depreciation & Amortization $890.0K $720.0K $840.0K
YoY Change 5.95% 227.27% 342.11%
% of Gross Profit 12.97% 16.44% 10.66%
Operating Expenses $15.65M $10.22M $17.70M
YoY Change -11.63% 18.56% 76.76%
Operating Profit -$3.599M -$5.840M -$6.968M
YoY Change -48.35% 30.94% 141.44%
Interest Expense -$1.691M $1.020M $526.0K
YoY Change -421.48% -508.0% -302.31%
% of Operating Profit
Other Income/Expense, Net -$188.0K $1.410M -$274.0K
YoY Change -31.39% -2920.0% 537.21%
Pretax Income -$4.411M -$16.43M -$10.93M
YoY Change -59.65% 245.17% 243.27%
Income Tax -$376.0K -$720.0K -$440.0K
% Of Pretax Income
Net Earnings -$3.968M -$15.48M -$10.47M
YoY Change -62.1% 225.2% 228.73%
Net Earnings / Revenue -32.94% -142.58% -97.53%
Basic Earnings Per Share -$0.19 -$0.73 -$0.77
Diluted Earnings Per Share -$0.19 -$0.73 -$0.77
COMMON SHARES
Basic Shares Outstanding 21.41M 21.27M 13.57M
Diluted Shares Outstanding 21.41M 21.27M 13.57M

Balance Sheet

Concept 2017 Q2 2016 Q4 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.100M $17.30M $17.10M
YoY Change -46.78% -42.14% -53.66%
Cash & Equivalents $18.66M $17.26M $17.14M
Short-Term Investments
Other Short-Term Assets $1.500M $1.200M $1.800M
YoY Change -16.67% -7.69% 157.14%
Inventory $6.300M $5.500M $8.700M
Prepaid Expenses
Receivables $3.000M $2.768M $4.900M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $19.90M $26.70M $32.50M
YoY Change -38.77% -22.3% -18.76%
LONG-TERM ASSETS
Property, Plant & Equipment $2.500M $2.900M $3.400M
YoY Change -26.47% 19.59% 32.86%
Goodwill $13.84M
YoY Change 15.28%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.600M $200.0K $200.0K
YoY Change 4700.0% 308.16%
Total Long-Term Assets $57.84M $50.00M $67.95M
YoY Change -14.89% 135.01% 218.12%
TOTAL ASSETS
Total Short-Term Assets $19.90M $26.70M $32.50M
Total Long-Term Assets $57.84M $50.00M $67.95M
Total Assets $77.74M $76.70M $100.5M
YoY Change -22.61% 37.86% 63.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.600M $3.100M $3.300M
YoY Change 9.09% 88.56% 174.31%
Accrued Expenses $8.700M $9.400M $10.90M
YoY Change -20.18% 70.91% 159.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $33.90M $22.85M $18.10M
YoY Change 87.29% 697.14% 660.5%
Total Short-Term Liabilities $54.20M $40.83M $38.20M
YoY Change 41.88% 302.21% 363.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.098M $10.07M
YoY Change -100.0% -91.48% -24.77%
Other Long-Term Liabilities $1.349M $1.222M $11.90M
YoY Change -88.66% 4264.29% 42400.0%
Total Long-Term Liabilities $1.349M $2.320M $10.07M
YoY Change -86.61% -82.04% -24.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.20M $40.83M $38.20M
Total Long-Term Liabilities $1.349M $2.320M $10.07M
Total Liabilities $65.75M $56.97M $68.60M
YoY Change -4.15% 117.9% 178.94%
SHAREHOLDERS EQUITY
Retained Earnings -$222.1M -$212.6M
YoY Change 22.8%
Common Stock $236.6M $235.7M
YoY Change 1964016.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.83M $19.48M $31.90M
YoY Change
Total Liabilities & Shareholders Equity $77.74M $76.73M $100.5M
YoY Change -22.65% 37.91% 63.77%

Cashflow Statement

Concept 2017 Q2 2016 Q4 2016 Q2
OPERATING ACTIVITIES
Net Income -$3.968M -$15.48M -$10.47M
YoY Change -62.1% 225.2% 228.73%
Depreciation, Depletion And Amortization $890.0K $720.0K $840.0K
YoY Change 5.95% 227.27% 342.11%
Cash From Operating Activities -$3.200M -$3.060M -$6.070M
YoY Change -47.28% -22.92% 248.85%
INVESTING ACTIVITIES
Capital Expenditures -$20.00K $80.00K -$170.0K
YoY Change -88.24% -200.0% -54.05%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$20.57M
YoY Change
Cash From Investing Activities -$20.00K $70.00K -$20.73M
YoY Change -99.9% -187.5% 5502.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 220.0K -2.130M 20.21M
YoY Change -98.91% 21200.0% 202000.0%
NET CHANGE
Cash From Operating Activities -3.200M -3.060M -6.070M
Cash From Investing Activities -20.00K 70.00K -20.73M
Cash From Financing Activities 220.0K -2.130M 20.21M
Net Change In Cash -3.000M -5.120M -6.590M
YoY Change -54.48% 26.11% 213.81%
FREE CASH FLOW
Cash From Operating Activities -$3.200M -$3.060M -$6.070M
Capital Expenditures -$20.00K $80.00K -$170.0K
Free Cash Flow -$3.180M -$3.140M -$5.900M
YoY Change -46.1% -19.28% 330.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1349000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
16322000
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
3475000
CY2017Q2 us-gaap Minority Interest
MinorityInterest
155000
CY2017Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
207000
CY2017Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
2203000
CY2017Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11986000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77738000
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
21000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
236617000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2724000
CY2017Q2 us-gaap Liabilities
Liabilities
65752000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-222083000
CY2016Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1098000
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
492000
CY2016Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
5208000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1222000
CY2016Q4 us-gaap Liabilities
Liabilities
56969000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
21000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
235673000
CY2016Q2 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
7249000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3659000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-212553000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
11831000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
19482000
CY2016Q4 us-gaap Minority Interest
MinorityInterest
279000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19761000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76730000
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21278373
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21278373
CY2017Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1000000
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2017Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
5894000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6057000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-3968000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-10470000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-274000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4411000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10933000
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-376000
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-440000
CY2017Q2 us-gaap Profit Loss
ProfitLoss
-4035000
CY2016Q2 us-gaap Profit Loss
ProfitLoss
-10493000
CY2017Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-67000
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.77
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-188000
CY2016Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-23000
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13568120
us-gaap Cost Of Services
CostOfServices
5624000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
4505000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
3056000
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.77
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21421016
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6302000
us-gaap Net Income Loss
NetIncomeLoss
-9530000
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21421016
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3143000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6401000
CY2016Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3356000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5393000
CY2017Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2016Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2017Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-64000
CY2016Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-97000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
15645000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
17703000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3599000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6968000
CY2016Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-526000
CY2017Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1067000
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21412480
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13568120
CY2016Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1408000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-11901000
CY2017Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-72000
CY2017Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
670000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5093000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-23000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-310000
us-gaap Operating Expenses
OperatingExpenses
30835000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13538000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-783000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3165000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10303000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20686000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-440000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6492000
us-gaap Profit Loss
ProfitLoss
-20246000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10634000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1958000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-285000
us-gaap Operating Expenses
OperatingExpenses
35773000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12143000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2481000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-874000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-659000
us-gaap Profit Loss
ProfitLoss
-9644000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-114000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11070000
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1691000
CY2016Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-3165000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
5195000
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21412480
CY2017Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3365000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-23000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1097000
us-gaap Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
170000
us-gaap Cost Of Goods Sold Depreciation
CostOfGoodsSoldDepreciation
1225000
cdna Amortization Of Deferred Revenue
AmortizationOfDeferredRevenue
12000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1769000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
56000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
982000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-252000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-236000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-845000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-336000
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
39000
us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
40000
us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
18000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-751000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2153000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9938000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12259000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
20567000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
34000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-128000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-20843000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
24002000
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
-9375000
us-gaap Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
0
cdna Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs
ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts
0
cdna Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs
ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts
20619000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
44000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
175000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
12871000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
232000
us-gaap Proceeds From Repayments Of Bank Overdrafts
ProceedsFromRepaymentsOfBankOverdrafts
176000
us-gaap Proceeds From Repayments Of Bank Overdrafts
ProceedsFromRepaymentsOfBankOverdrafts
-196000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1976000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
20375000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-64000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-17000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8154000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-12744000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.58
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12768913
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12768913
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1408000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-21654000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-23000
us-gaap Net Income Loss
NetIncomeLoss
-20223000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21378321
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21378321
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
934000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-8710000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-124000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21631000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12854227
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5406712
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3293000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11878000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8586000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1821000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
152000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
189000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
422000
us-gaap Increase Decrease In Accrued Salaries
IncreaseDecreaseInAccruedSalaries
-486000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
542000
cdna Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2016 cdna Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29888000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17144000
CY2017Q2 cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
1064000
CY2016Q2 cdna Business Acquisition Deferred Payment Consideration
BusinessAcquisitionDeferredPaymentConsideration
5700000
cdna Debt Assumed As Part Of Acquisition
DebtAssumedAsPartOfAcquisition
13421000
us-gaap Convertible Preferred Stock Converted To Other Securities
ConvertiblePreferredStockConvertedToOtherSecurities
13064000
cdna Common Shares Issued As Part Of Acquisition
CommonSharesIssuedAsPartOfAcquisition
7205000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to (i)&#160;revenue recognition, (ii)&#160;the differences between amounts billed and estimated receipts from payers, (iii)&#160;the determination of the accruals for clinical studies, (iv)&#160;the determination of refunds to be requested by third-party payers, (v)&#160;the fair value of assets and liabilities, including from acquisitions, (vi)&#160;inventory valuation, (vii) the valuation of warrants, Series A Preferred, and common stock issued in the Private Placement and Subsequent Financing, (viii)&#160;the fair value of contingent consideration in a business acquisition, (ix) the fair value of embedded derivatives, (x) measurement of stock-based compensation expense, (xi)&#160;the determination of the valuation allowance and estimated tax benefit associated with deferred tax assets and net deferred tax liability, (xii)&#160;any impairment of long-lived assets, including in-process technology and goodwill, and (xiii)&#160;legal contingencies. Actual results could differ from those estimates.</p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents and accounts receivable. The Company&#8217;s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper and various bank deposit accounts. The counterparties to the agreements relating to the Company&#8217;s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets which may be in excess of insured limits.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its accounts receivable, which are derived from revenue earned from AlloMap tests provided for patients located in the U.S. and billed to various third-party payers, and sales of Olerup products to distributors, strategic partners and end customers in Europe, Middle East and Africa, the U.S., Latin America and other geographic regions. The Company has not experienced any significant credit losses and does not generally require collateral on receivables. <font style="color:#000000;"> </font>For the six months ended June 30, 2017 and 2016, approximately 28% and 48%, respectively, of total revenue was derived from Medicare. No other payers represented more than 10% of total revenue for these periods.&#160; At June 30, 2017, Medicare accounted for approximately 26% of accounts receivable. At December&#160;31, 2016, Medicare accounted for approximately 27% of accounts receivable. No other payers or customers represented more than 10% of accounts receivable at either June 30, 2017 or December&#160;31, 2016. </p></div>
us-gaap Revenue Recognition Multiple Element Arrangements
RevenueRecognitionMultipleElementArrangements
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Collaboration, License and Other Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generates revenue from collaboration and license agreements. Collaboration and license agreements may include non-refundable upfront payments, partial or complete reimbursement of research and development costs, contingent payments based on the occurrence of specified events under the agreements, license fees and royalties on sales of products or product candidates if they are successfully commercialized. The Company&#8217;s performance obligations under the collaborations may include the transfer of intellectual property rights in the form of licenses, obligations to provide research and development services and obligations to participate on certain development committees with the collaboration partners. The Company makes judgments that affect the periods over which it recognizes revenue. The Company periodically reviews its estimated periods of performance based on the progress under each arrangement and accounts for the impact of any change in estimated periods of performance on a prospective basis. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes contingent consideration received from the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved, which the Company believes is consistent with the substance of its performance under its various license and collaboration agreements. The Company did not recognize any revenue connected with milestones during the three and six months ended June 30, 2017 or 2016.</p></div>
us-gaap Advertising Cost Policy Expensed Advertising Cost
AdvertisingCostPolicyExpensedAdvertisingCost
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Advertising Expenses</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All advertising costs are expensed as incurred. Advertising expenses were insignificant during all of the periods presented. </p></div>
cdna Schedule Of Maturities Of Debt Table Tex Block
ScheduleOfMaturitiesOfDebtTableTexBlock
<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2017, future debt maturities were as follows (in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.36%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ending December 31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.36%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remainder of 2017</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,569</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,168</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,250</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,155</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt maturities</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,142</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: debt discount and issuance costs</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,252</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total debt maturities, net of debt discount and issuance costs</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,890</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.36%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion of long-term debt</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,890</p></td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.36%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term debt, net carrying value</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2017Q2 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
33900000
us-gaap Additional Cash And Cash Equivalent Related Text
AdditionalCashAndCashEquivalentRelatedText
Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q2 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3968000
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10470000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9530000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-20223000
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12854227
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5406712
CY2016Q2 cdna Preferred Stock Issued Shares Private Placement
PreferredStockIssuedSharesPrivatePlacement
4630145
CY2016Q2 cdna Preferred Stock Issued Shares Subsequent Financing
PreferredStockIssuedSharesSubsequentFinancing
4630145
CY2016Q4 us-gaap Goodwill Gross
GoodwillGross
26860000
CY2016Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
13021000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
85000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
39000
CY2017Q2 us-gaap Goodwill Gross
GoodwillGross
26984000
CY2017Q2 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
14979000
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1220000
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2438000
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2438000
CY2017Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
393000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1200000
us-gaap Number Of Reporting Units
NumberOfReportingUnits
2
CY2016Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
374000
CY2017Q2 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
276000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
500000
CY2017Q2 cdna Indefinite Lived Intangible Assets Excluding Goodwill Gross
IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
6700000
us-gaap New Date Of Annual Goodwill Impairment Test
NewDateOfAnnualGoodwillImpairmentTest
On January 1, 2017, the Company adopted ASU 2017-04, which eliminated the Step 2 requirement of the goodwill impairment test. Instead, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. The new standard simplifies how an entity is required to test goodwill for impairment and reduces the cost and complexity of evaluating goodwill for impairment. The Company determined that the decrease in its market capitalization constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017.
CY2017Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
31225000
CY2017Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2395000
CY2017Q2 cdna Finite Lived Intangible Foreign Currency Translation
FiniteLivedIntangibleForeignCurrencyTranslation
1737000
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
27093000
CY2017Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
37875000
CY2017Q2 cdna Intangible Assets Excluding Goodwill Accumulated Amortization
IntangibleAssetsExcludingGoodwillAccumulatedAmortization
2395000
CY2017Q2 cdna Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss
IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss
1737000
CY2017Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
600000
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2438000
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2438000
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2438000
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
13683000
CY2017Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
3158000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4199000
CY2017Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1896000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
159000
CY2017Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1289000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1103000
CY2017Q2 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
1375000
CY2016Q4 cdna Accrued Clinical And Cost Of Other Studies Current
AccruedClinicalAndCostOfOtherStudiesCurrent
1375000
CY2017Q2 us-gaap Interest Payable Current
InterestPayableCurrent
1009000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
862000
CY2017Q2 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
571000
CY2016Q4 cdna Accrued Sample Processing Fees
AccruedSampleProcessingFees
524000
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
414000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
345000
CY2016Q4 us-gaap Customer Refund Liability Current
CustomerRefundLiabilityCurrent
281000
CY2017Q2 cdna Accrued Tax Audit And Compliance Related Fees Current
AccruedTaxAuditAndComplianceRelatedFeesCurrent
250000
CY2016Q4 cdna Accrued Tax Audit And Compliance Related Fees Current
AccruedTaxAuditAndComplianceRelatedFeesCurrent
275000
CY2017Q2 cdna Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
135000
CY2016Q4 cdna Accrued Software Implementation Costs
AccruedSoftwareImplementationCosts
176000
CY2017Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
37000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
68000
CY2017Q2 cdna Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
0
CY2016Q4 cdna Accrued Debt Financing Fees Current
AccruedDebtFinancingFeesCurrent
600000
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
500000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
440000
cdna Leases Expiration Period
LeasesExpirationPeriod
2020
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
900000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2017Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2017Q2 us-gaap Royalty Revenue
RoyaltyRevenue
0.2
CY2016Q2 us-gaap Fees And Commissions Transfer Agent
FeesAndCommissionsTransferAgent
1800000
cdna Additional Issued Units
AdditionalIssuedUnits
334169
CY2016Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
CY2017Q2 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
21000
CY2017Q2 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
25000
CY2017Q2 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
5000
CY2017Q2 us-gaap Capital Leases Future Minimum Payments Due In Four Years
CapitalLeasesFutureMinimumPaymentsDueInFourYears
0
CY2017Q2 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
51000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1094000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2116000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2068000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2027000
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7305000
CY2016Q3 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
1300000
CY2016Q4 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
1000000
CY2016Q4 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
100000
CY2017Q1 us-gaap Loss Contingency Accrual Payments
LossContingencyAccrualPayments
1000000
CY2017Q1 us-gaap Loss Contingency Accrual Payments
LossContingencyAccrualPayments
100000
cdna Description Of Agreement Expected Expiration Year
DescriptionOfAgreementExpectedExpirationYear
The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
CY2013Q2 cdna Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
250000
CY2013Q2 cdna Potential Refundable Portion Of Upfront Payment
PotentialRefundablePortionOfUpfrontPayment
267000
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
387500
CY2013Q2 cdna Upfront Payment In Cash
UpfrontPaymentInCash
414000
CY2017Q2 cdna Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
10000
CY2016Q2 cdna Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
16000
cdna Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
19000
cdna Revenues And Royalties Recognized
RevenuesAndRoyaltiesRecognized
31000
CY2016Q2 us-gaap Royalty Revenue
RoyaltyRevenue
0
us-gaap Royalty Revenue
RoyaltyRevenue
0.2
us-gaap Royalty Revenue
RoyaltyRevenue
100000
CY2017Q2 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
0
CY2016Q4 cdna Royalty Revenue Receivable
RoyaltyRevenueReceivable
0
CY2017Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1000000
CY2016Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
800000
CY2017Q2 cdna Long Term Debt Maturities Repayments Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsRemainderOfFiscalYear
4569000
CY2017Q2 cdna Long Term Debt Maturities Repayments In Year Two
LongTermDebtMaturitiesRepaymentsInYearTwo
17168000
CY2017Q2 cdna Long Term Debt Maturities Repayments In Year Three
LongTermDebtMaturitiesRepaymentsInYearThree
11250000
CY2017Q2 cdna Long Term Debt Maturities Repayments In Year Four
LongTermDebtMaturitiesRepaymentsInYearFour
7155000
CY2017Q2 cdna Long Term Debt Maturities Repayments
LongTermDebtMaturitiesRepayments
40142000
CY2017Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
6252000
CY2017Q2 us-gaap Long Term Debt
LongTermDebt
33890000
CY2015Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
20000000
CY2017Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
11200000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
200000
cdna Prepayment Penalty
PrepaymentPenalty
0.00
CY2016Q2 cdna Common Stock Purchase Price
CommonStockPurchasePrice
3.99
CY2016Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
1700000
CY2016Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1002507
CY2017Q2 cdna Estimated Fair Value Of Warrant Liability Remeasurement Charge
EstimatedFairValueOfWarrantLiabilityRemeasurementCharge
500000
cdna Estimated Fair Value Of Warrant Liability Remeasurement Charge
EstimatedFairValueOfWarrantLiabilityRemeasurementCharge
3400000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
365074
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
357075
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
65510
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
212739
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
39757
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
444867
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
358600
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod
0
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1792286
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1898390
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.15
cdna Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.93
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.94
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.04
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2017Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
1178584
CY2017Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
626539
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1805123
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
6.03
CY2017Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
4.56
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.52
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
P6Y5M12D
cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P8Y9M7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y3M4D
CY2017Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
109000
CY2017Q2 cdna Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
10000
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
119000
CY2017Q2 us-gaap Share Price
SharePrice
1.11
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.52
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.01
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.06
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
300000
CY2017Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1100000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M17D
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
495000
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
367000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
886000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
812000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0
CY2017Q2 cdna Intersegment Sales
IntersegmentSales
0
cdna Intersegment Sales
IntersegmentSales
0
CY2017Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
887000
CY2016Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
836000

Files In Submission

Name View Source Status
0001564590-17-017296-index-headers.html Edgar Link pending
0001564590-17-017296-index.html Edgar Link pending
0001564590-17-017296.txt Edgar Link pending
0001564590-17-017296-xbrl.zip Edgar Link pending
cdna-10q_20170630.htm Edgar Link pending
cdna-20170630.xml Edgar Link completed
cdna-20170630.xsd Edgar Link pending
cdna-20170630_cal.xml Edgar Link unprocessable
cdna-20170630_def.xml Edgar Link unprocessable
cdna-20170630_lab.xml Edgar Link unprocessable
cdna-20170630_pre.xml Edgar Link unprocessable
cdna-ex101_405.htm Edgar Link pending
cdna-ex102_404.htm Edgar Link pending
cdna-ex103_403.htm Edgar Link pending
cdna-ex311_7.htm Edgar Link pending
cdna-ex312_8.htm Edgar Link pending
cdna-ex321_9.htm Edgar Link pending
cdna-ex47_402.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending